EPISODE · Apr 17, 2024 · 20 MIN
Allergic asthma immunotherapy, with Dr. Klaus Bønnelykke
from Thorax Podcast · host BMJ Group
Asthma prevalence is increasing around the world, and is theorised to be due to a number of environmental factors. One such factor is a sensitivity to house dust mite (HDM) allergens, which is common in asthma patients. Dr. Klaus Bønnelykke (1) joins the podcast to speak with Dr. Kate Diomede about this topic, following the publication of the paper, "Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma". (1) Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital, Copenhagen, Denmark Please engage in the conversation through the social media channels (Twitter - @ThoraxBMJ; Facebook - Thorax.BMJ) and subscribe on your preferred platform, to get the latest episodes directly on your device each month. We would love to hear your thoughts on the podcast, you can leave a review on Apple Podcasts or Spotify.
What this episode covers
Asthma prevalence is increasing around the world, and is theorised to be due to a number of environmental factors. One such factor is a sensitivity to house dust mite (HDM) allergens, which is common in asthma patients. Dr. Klaus Bønnelykke (1) joins the podcast to speak with Dr. Kate Diomede about this topic, following the publication of the paper, "Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma". (1) Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital, Copenhagen, Denmark Please engage in the conversation through the social media channels (Twitter - @ThoraxBMJ; Facebook - Thorax.BMJ) and subscribe on your preferred platform, to get the latest episodes directly on your device each month. We would love to hear your thoughts on the podcast, you can leave a review on Apple Podcasts or Spotify.
NOW PLAYING
Allergic asthma immunotherapy, with Dr. Klaus Bønnelykke
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m